Nucleoside phosphorylase is an enzyme which cleaves a nucleoside by phosphorylating the ribose to produce a nucleobase and ribose 1 phosphate. It is one enzyme of the nucleotide salvage pathways. These pathways allow the cell to produce nucleotide monophosphates when the de novo synthesis pathway has been interrupted or is non-existent (as is the case in the brain). Often the de novo pathway is interrupted as a result of chemotherapy drugs such as methotrexate or aminopterin.
All salvage pathway enzymes require a high energy phosphate donor such as ATP or PRPP.
Adenosine uses the enzyme adenosine kinase, which is a very important enzyme in the cell. Attempts are being made to develop an inhibitor for the enzyme for use in cancer chemotherapy.
PNPase together with adenosine deaminase (ADA), serves a key role in purine catabolism, referred to as the salvage pathway. Mutations in ADA lead to an accumulation of (d)ATP, which inhibits ribonucleotide reductase, leading to a deficiency in (d)CTPs and (d)TTPs, which, in turn, induces apoptosis in T-lymphocytes and B-lymphocytes, leading to severe combined immunodeficiency (SCID).citation needed
PNP-deficient patients will have an immunodeficiency problem. It affects only T-cells; B-cells are unaffected by the deficiency.
^Canduri, F.; Dos Santos, D. M.; Silva, R. G.; Mendes, M. A.; Basso, L. A.; Palma, M. S.; De Azevedo, W. F.; Santos, D. S. (2004). "Structures of human purine nucleoside phosphorylase complexed with inosine and ddI". Biochemical and Biophysical Research Communications313 (4): 907–914. doi:10.1016/j.bbrc.2003.11.179. PMID14706628.
Borgers M, Verhaegen H, De Brabander M, et al. (1978). "Purine nucleoside phosphorylase in chronic lymphocytic leukemia (CLL).". Blood52 (5): 886–95. PMID100152.
Andrews LG, Markert ML (1992). "Exon skipping in purine nucleoside phosphorylase mRNA processing leading to severe immunodeficiency.". J. Biol. Chem.267 (11): 7834–8. PMID1560016.
Ealick SE, Rule SA, Carter DC, et al. (1990). "Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution.". J. Biol. Chem.265 (3): 1812–20. PMID2104852.
Williams SR, Gekeler V, McIvor RS, Martin DW (1987). "A human purine nucleoside phosphorylase deficiency caused by a single base change.". J. Biol. Chem.262 (5): 2332–8. PMID3029074.
Pannicke U, Tuchschmid P, Friedrich W, et al. (1997). "Two novel missense and frameshift mutations in exons 5 and 6 of the purine nucleoside phosphorylase (PNP) gene in a severe combined immunodeficiency (SCID) patient.". Hum. Genet.98 (6): 706–9. doi:10.1007/s004390050290. PMID8931706.
Stoeckler JD, Poirot AF, Smith RM, et al. (1997). "Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis.". Biochemistry36 (39): 11749–56. doi:10.1021/bi961971n. PMID9305964.
Sasaki Y, Iseki M, Yamaguchi S, et al. (1998). "Direct evidence of autosomal recessive inheritance of Arg24 to termination codon in purine nucleoside phosphorylase gene in a family with a severe combined immunodeficiency patient.". Hum. Genet.103 (1): 81–5. doi:10.1007/s004390050787. PMID9737781.
Dalal I, Grunebaum E, Cohen A, Roifman CM (2001). "Two novel mutations in a purine nucleoside phosphorylase (PNP)-deficient patient.". Clin. Genet.59 (6): 430–7. doi:10.1034/j.1399-0004.2001.590608.x. PMID11453975.
Falkenberg M, Gaspari M, Rantanen A, et al. (2002). "Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA.". Nat. Genet.31 (3): 289–94. doi:10.1038/ng909. PMID12068295.
Stoychev G, Kierdaszuk B, Shugar D (2002). "Xanthosine and xanthine. Substrate properties with purine nucleoside phosphorylases, and relevance to other enzyme systems.". Eur. J. Biochem.269 (16): 4048–57. doi:10.1046/j.1432-1033.2002.03097.x. PMID12180982.